 EyeGene expected to utilize TriLinks CleanCap technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials EyeGene expected to utilize TriLinks CleanCap technology and modified UTP manufactured by TriLink in the production of its EG-COVID mRNA COVID-19 vaccine for clinical trials 